Omeros (OMER) announced statistical analysis results related to the expanded access program for narsoplimab, Omeros’ ...
Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...
Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations ...
In other recent news, Omeros Corporation has announced promising results from its investigational drug, narsoplimab, in reducing mortality for patients with thrombotic microangiopathy (TA-TMA ...
Both presentations report real world outcomes from patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab supplied by Omeros under ...
Solid Biosciences (SLDB) announced initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy ...
Stocktwits on MSN3d
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move?Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...
The following is a summary of “Steroid-resistant nephrotic syndrome due to renal-limited thrombotic microangiopathy and membranous nephropathy after allogeneic hematopoietic stem cell transplantation ...
Research analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a report released on Thursday. The brokerage set a “sell” rating on the ...
Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...
in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication in both adult and pediatric hematopoietic stem cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback